Oslo universitetssykehus HF

Oslo 379

1 studies enrolling now · 10 studies all time

What they study most

Anemia, Hemophilia A, Heterozygous Familial Hypercholesterolemia, Hyperlipidemia, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Ovarian Cancer, Low-grade Serous Peritoneal Cancer, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Myelodysplastic Syndrome, Neoplasm Metastasis

Studies at this site

• A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions — Recruiting now
• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma — Completed
• A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies — Running, not enrolling
• A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) — Stopped early
• A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer — Stopped early
• BAX 855 PK-guided Dosing — Completed
• Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients — Completed
• Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events — Completed
• A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia — Completed
• A Non-Interventional Follow-Up to the VELOUR Study - Translational Research — Status unconfirmed